Toxicological Reviews

, Volume 25, Issue 2, pp 79–85 | Cite as

Does High-Dose Buprenorphine Cause Respiratory Depression?

Possible Mechanisms and Therapeutic Consequences
  • Bruno Mégarbane
  • Raymond Hreiche
  • Stéphane Pirnay
  • Nicolas Marie
  • Frédéric J. Baud
Review Article


Buprenorphine is an opioid agonist-antagonist with a ‘ceiling effect’ for respiratory depression. Compared with methadone, its unique pharmacology offers practical advantages and enhanced safety when prescribed as recommended and supervised by a physician. Buprenorphine has been approved in several countries as an efficient and safe maintenance therapy for heroin addiction. Its use resulted in a salutary effect with a reduction in heroin overdose-related deaths in countries that implemented office-based buprenorphine maintenance. In France, however, where high-dose buprenorphine has been marketed since 1996, several cases of asphyxic deaths were reported among addicts treated with buprenorphine. Death resulted from buprenorphine intravenous misuse or concomitant sedative drug ingestion, such as benzodiazepines. In these situations of abuse, misuse, or in association with elevated doses of psychotropic drugs, buprenorphine may cause severe respiratory depression. Unlike other opiates, the respiratory effects from buprenorphine are not responsive to naloxone. However, the exact mechanism of buprenorphine-induced effects on ventilation is still unknown. The role of norbuprenorphine, the main N-dealkylated buprenorphine metabolite with potent respiratory depressor activity, also remains unclear. Experimental studies investigating the respiratory effects of combinations of high doses of buprenorphine and benzodiazepines suggested that this drug-drug interaction may result from a pharmacodynamic interaction. A pharmacokinetic interaction between buprenorphine and flunitrazepam is also considered. As there are many questions regarding the possible dangers of death or respiratory depression associated with buprenorphine use, we aimed to present a comprehensive critical review of the published clinical and experimental studies on buprenorphine respiratory effects.



The authors would like to acknowledge Dr Rebeca Gracia, PharmD, DABAT, from the North Texas Poison Center, Dallas, USA for her helpful review of this manuscript.

No source of funds was used to assist in the preparation of this manuscript. The authors are not aware of any potential conflicts of interest directly relevant to the content of this review.


  1. 1.
    Darke S, Zador D. Fatal heroin’ overdose’: a review. Addiction 1996; 91: 1765–72PubMedCrossRefGoogle Scholar
  2. 2.
    Warner-Smith M, Darke S, Lynskey M, et al. Heroin overdose: causes and consequences. Addiction 2001; 96: 1113–25PubMedCrossRefGoogle Scholar
  3. 3.
    Sporer KA. Buprenorphine: a primer for emergency physicians. Ann Emerg Med 2004; 43: 580–4PubMedCrossRefGoogle Scholar
  4. 4.
    Auriacombe M, Fatseas M, Dubernet J, et al. French field experience with buprenorphine. Am J Addict 2004; 13Suppl. 1: S17–28PubMedCrossRefGoogle Scholar
  5. 5.
    Feroni I, Aubisson S, Bouhnik AD, et al. Collaboration between general practitioners and pharmacists in the management of patients on high-dosage buprenorphine treatment: prescribers’ practices [in French]. Presse Med 2005; 34: 1213–9PubMedCrossRefGoogle Scholar
  6. 6.
    Gueye PN, Mégarbane B, Borron SW, et al. Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995–99. Addiction 2000; 97: 1295–304CrossRefGoogle Scholar
  7. 7.
    Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviors and associated health outcomes in France, 1996–2003. Addiction 2005; 100: 1690–700PubMedCrossRefGoogle Scholar
  8. 8.
    Reisine T, Pasternak G. Opioid analgesics and antagonists. In: Hardman J, Limbird L, Molinoff P, et al., editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 521–55Google Scholar
  9. 9.
    Huang P, Kehner GB, Cowan A, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001; 297: 688–95PubMedGoogle Scholar
  10. 10.
    Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine: the significance of receptor binding. Br J Anaesth 1985; 57: 192–6PubMedCrossRefGoogle Scholar
  11. 11.
    Boysen K, Hertel S, Chraemmer-Jorgensen B, et al. Buprenorphine antagonism of ventilatory depression following fentanyl anaesthesia. Acta Anaesthesiol Scand 1988; 32: 490–2PubMedCrossRefGoogle Scholar
  12. 12.
    Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005; 44: 661–80PubMedCrossRefGoogle Scholar
  13. 13.
    Chang Y, Moody DE, McCance-Katz EF. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos 2006; 34: 440–8PubMedGoogle Scholar
  14. 14.
    Obadia Y, Perrin V, Feroni I, et al. Injecting misuse of buprenorphine among french drug users. Addiction 2001; 96: 267–72PubMedCrossRefGoogle Scholar
  15. 15.
    Comer SD, Collins ED, Fischman MW. Intravenous buprenorphine self-administration by detoxified heroin abusers. J Pharmacol Exp Ther 2001; 301: 266–76CrossRefGoogle Scholar
  16. 16.
    Jenkinson RA, Clark NC, Fry CL, et al. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005; 100: 197–205PubMedCrossRefGoogle Scholar
  17. 17.
    Robinson GM, Dukes PD, Robinson BJ, et al. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend 1993; 33: 81–6PubMedCrossRefGoogle Scholar
  18. 18.
    Reynaud M, Tracqui A, Petit G, et al. Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. Am J Psychiatry 1998; 155: 448–9PubMedGoogle Scholar
  19. 19.
    Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998; 22: 430–4PubMedGoogle Scholar
  20. 20.
    Gaulier JM, Marquet P, Lacassie E, et al. Fatal intoxication following self-administration of a massive dose of buprenorphine. J Forensic Sci 2000; 45: 226–8PubMedGoogle Scholar
  21. 21.
    Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001; 121: 65–9PubMedCrossRefGoogle Scholar
  22. 22.
    Kintz P. A new series of 13 buprenorphine-related deaths. Clin Biochem 2002; 35: 513–6PubMedCrossRefGoogle Scholar
  23. 23.
    Pirnay S, Borron SW, Giudicelli CP, et al. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004; 99: 978–88PubMedCrossRefGoogle Scholar
  24. 24.
    Steentoft A, Teige B, Holmgren P, et al. Fatal poisoning in Nordic drug addicts in 2002. Forensic Sci Int 2006; 160(2–3): 148–56PubMedCrossRefGoogle Scholar
  25. 25.
    Schifano F, Corkery J, Gilvarry E, et al. Buprenorphine mortality, seizures and prescription data in the UK, 1980–2002. Hum Psychopharmacol 2005; 20: 343–8PubMedCrossRefGoogle Scholar
  26. 26.
    Serfaty M, Masterton G. Fatal poisonings attributed to benzodiazepines in Britain during the 1980s. Br J Psychiatry 1993; 163: 386–93PubMedCrossRefGoogle Scholar
  27. 27.
    Cowan A, Doxey J, Harry E. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 1977; 60: 547–54PubMedCrossRefGoogle Scholar
  28. 28.
    Verborgh C, De Coster R, D’Haese J, et al. Effects of chlordiazepoxide on opioid-induced antinociception and respiratory depression in restrained rats. Pharmacol Biochem Behav 1998; 59: 663–70PubMedCrossRefGoogle Scholar
  29. 29.
    McCormick GY, White WJ, Zagon IS, et al. Effects of diazepam on arterial blood gas concentrations and pH of adult rats acutely and chronically exposed to methadone. J Pharmacol Exp Ther 1984; 230: 353–9PubMedGoogle Scholar
  30. 30.
    Ohtani M, Kotaki H, Nishitateno K, et al. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 1997; 281: 428–33PubMedGoogle Scholar
  31. 31.
    Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55: 569–80PubMedCrossRefGoogle Scholar
  32. 32.
    Nielsen S, Taylor DA. The effect of buprenorphine and benzodiazepines on respiration in the rat. Drug Alcohol Depend 2005; 79: 95–101PubMedCrossRefGoogle Scholar
  33. 33.
    Gueye PN, Borron SW, Risède P, et al. Lack of effect of single high doses of buprenorphine on arterial blood gases in the rat. Toxicol Sci 2001; 62: 148–54PubMedCrossRefGoogle Scholar
  34. 34.
    Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006; 96: 627–32PubMedCrossRefGoogle Scholar
  35. 35.
    Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 2005; 94: 825–34PubMedCrossRefGoogle Scholar
  36. 36.
    Molke Jensen F, Jensen NH, Holk IK, et al. Prolonged and biphasic respiratory depression following epidural buprenorphine. Anaesthesia 1987; 42: 470–5PubMedCrossRefGoogle Scholar
  37. 37.
    Cicero TJ, Inciardi JA. Potential for abuse of buprenorphine in office-based treatment of opioid dependence. N Engl J Med 2005; 353: 1863–4PubMedCrossRefGoogle Scholar
  38. 38.
    Rainey HB. Abuse of buprenorphine. N Z Med J 1986; 99: 72PubMedGoogle Scholar
  39. 39.
    Boyd J, Randell T, Luurila H, et al. Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiol Scand 2003; 47: 1031–3PubMedCrossRefGoogle Scholar
  40. 40.
    Gal TJ. Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol Ther 1989; 45: 66–71PubMedCrossRefGoogle Scholar
  41. 41.
    Ohtani M, Kotaki H, Uchino K, et al. Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats. Drug Metab Dispos 1994; 22: 2–7PubMedGoogle Scholar
  42. 42.
    Ohtani M, Kotaki H, Sawada Y, et al. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995; 272: 505–10PubMedGoogle Scholar
  43. 43.
    Mégarbane B, Marie N, Pirnay S, et al. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol Appl Pharmacol 2006; 212: 256–67PubMedCrossRefGoogle Scholar
  44. 44.
    Gopal S, Tzeng TB, Cowan A. Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine. Eur J Pharm Sci 2002; 15: 287–9PubMedCrossRefGoogle Scholar
  45. 45.
    Debruyne D, Quentin T, Poisnel G, et al. Acute and chronic administration of clorazepate modifies the cell surface regulation of mu opioid receptors induced by buprenorphine in specific regions of the rat brain. Brain Res 2005; 1052: 222–31PubMedCrossRefGoogle Scholar
  46. 46.
    Quentin T, Debruyne D, Lelong-Boulouard V, et al. Clorazepate affects cell surface regulation of delta and kappa opioid receptors, thereby altering buprenorphine-induced adaptation in the rat brain. Brain Res 2005; 1063: 84–95PubMedCrossRefGoogle Scholar
  47. 47.
    Borron SW, Monier C, Risède P, et al. Flunitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat. Hum Exp Toxicol 2002; 21: 599–605PubMedCrossRefGoogle Scholar
  48. 48.
    Gueye PN, Borron SW, Risède P, et al. Buprenorphine and midazolam act in combination to depress respiration in rats. Toxicol Sci 2002; 65: 107–14PubMedCrossRefGoogle Scholar
  49. 49.
    Shah N, Patel V, Donald A. Effect of diazepam, desmethylimipramine, and SKF 525-A on the disposition of levo-methadone in mice after single or double injection. Drug Metab Dispos 1979; 7: 241–2PubMedGoogle Scholar
  50. 50.
    Pond SM, Tong TG, Benovitz NL, et al. Lack of effect of diazepam on methadone metabolism in methadone-maintained addicts. Clin Pharmacol Ther 1982; 31: 139–43PubMedCrossRefGoogle Scholar
  51. 51.
    Ibrahim RB, Wilson JG, Thorsby ME, et al. Effect of buprenorphine on CYP3A activity in rat and human liver microsomes. Life Sci 2000; 66: 1293–8PubMedCrossRefGoogle Scholar
  52. 52.
    Kilicarslan T, Sellers EM. Lack of interaction of buprenorphine with flunitrazepam metabolism. Am J Psychiatry 2000; 157: 1164–6PubMedCrossRefGoogle Scholar
  53. 53.
    Mégarbane B, Pirnay S, Borron SW, et al. Flunitrazepam does not alter cerebral distribution of buprenorphine in the rat. Toxicol Lett 2005; 157: 211–9PubMedCrossRefGoogle Scholar
  54. 54.
    Kalyuzhny AE, Dooyema J, Wessendorf MW. Opioid- and GABA(A)-receptors are co-expressed by neurons in rat brain. Neuroreport 2000; 11: 2625–8PubMedCrossRefGoogle Scholar
  55. 55.
    Yamada KA, Norman WP, Hamosh P, et al. Medullary ventral surface GABA receptors affect respiratory and cardiovascular function. Brain Res 1982; 248: 71–8PubMedCrossRefGoogle Scholar
  56. 56.
    Dan’ura T, Kurokawa T, Yamashita A, et al. Inhibition of rat brain adenylate cyclase activity by benzodiazepine through the effects on Gi and catalytic proteins. Life Sci 1988; 42: 469–75PubMedCrossRefGoogle Scholar
  57. 57.
    Yanez A, Sabbe MB, Stevens CW, et al. Interaction of midazolam and morphine in the spinal cord of the rat. Neuropharmacology 1990; 29: 359–64PubMedCrossRefGoogle Scholar
  58. 58.
    Cox RF, Collins MA. The effects of benzodiazepines on human opioid receptor binding and function. Anesth Analg 2001; 93: 354–8PubMedGoogle Scholar
  59. 59.
    Gueye PN, Lofaso F, Borron SW, et al. Mechanism of respiratory insufficiency in pure or mixed drug-induced coma involving benzodiazepines. J Toxicol Clin Toxicol 2002; 40: 35–47PubMedCrossRefGoogle Scholar
  60. 60.
    Catley DM, Thornton C, Jordan C, et al. Pronounced, episodic oxygen desaturation in the postoperative period: its association with ventilatory pattern and analgesic regimen. Anesthesiology 1985; 63: 20–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Bruno Mégarbane
    • 1
    • 2
  • Raymond Hreiche
    • 1
  • Stéphane Pirnay
    • 1
    • 3
  • Nicolas Marie
    • 1
  • Frédéric J. Baud
    • 1
    • 2
  1. 1.Université Paris 7, Université Paris 5, Hôpital Fernand WidalINSERM U705, CNRS, UMR 7157ParisFrance
  2. 2.Réanimation Médicale et Toxicologique, Université Paris 7Assistance Publique - Hôpitaux de Paris, Hôpital LariboisièreParisFrance
  3. 3.Laboratoire de Toxicologie de la Préfecture de PoliceParisFrance

Personalised recommendations